VEGFA and peripheral arterial disease: Although VEGF‐A therapy was once thought to be an attractive treatment option in the context of PAD, it proved disappointing in clinical trials [10, 11], necessitating investigation into alternative mechanisms that contribute to angiogenesis in PAD.